Purchase Order 75N95022P00370
Award Date
7/14/22
Potential Completion Date
12/31/22
Potential Value
$702K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Danaher Corporation
PSC Category
6505 - Drugs And Biologicals
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Coralville, IA 52241, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences to Integrated DNA Technologies, Inc. (IDT), a manufacturer of nucleic acid products, for the custom synthesis of 1,536 antisense oligonucleotides in support of the SARS-CoV2 project. The potential value of this contract is $102,912.00. IDT has previously received awards from federal agencies such as the NIH, Centers for Disease Control and...
This is a $23,851.14 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, to Integrated DNA Technologies, Inc. (IDT) for the custom synthesis of 56 antisense oligonucleotides (ASOs) for an in-vivo liver toxicology study. The award has an ultimate completion date of September 30, 2024. IDT is a leading provider of specialized nucleic acid products and services to...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a Firm Fixed Price purchase order to Integrated DNA Technologies, Inc. (IDT) for the custom synthesis of 9 antisense oligonucleotides (ASOs) in support of a liver toxicity study. The order has a potential value of $24,912.77 and a completion date of August 24, 2023. IDT is a manufacturer of nucleic acid products that has previously provided a range of goods and...
This is a $14,996.96 firm-fixed-price contract awarded to Integrated DNA Technologies, Inc. (IDT) by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID). The contract is for the provision of custom oligonucleotide and RNA synthesis services. This is a call against a $100 million Blanket Purchase Agreement (BPA) between IDT and the NIH Office of Logistics and Acquisition Operations, which covers the delivery of various biological,...
This is a firm-fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Integrated DNA Technologies, Inc. (IDT), a leading provider of specialized nucleic acid products and services to the U.S. federal government. The $5,040 contract does not have a set-aside designation. Under this contract, IDT is supplying custom DNA and RNA oligonucleotides, gene fragments, next-generation sequencing products, primers, probes, and other reagents to support a...
The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a firm fixed price purchase order to Integrated DNA Technologies, Inc. (IDT) for the custom synthesis of 1,536 antisense oligonucleotides targeting the CHCHD10 gene. The $102,915.50 contract has an August 29, 2022 completion date and does not have a set-aside designation. IDT is a manufacturer of nucleic acid products that has previously supported...
This federal contract award was issued by the National Institutes of Health (NIH) Clinical Center to Integrated DNA Technologies, Inc. (IDT), a leading provider of specialized nucleic acid products and services to the U.S. federal government. The $95,173.74 firm-fixed-price purchase order does not have a set-aside designation. IDT has provided a diverse array of products and services through its federal contract awards, including custom DNA oligonucleotides, antisense oligonucleotides for...
This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Integrated DNA Technologies, Inc. (IDT), a leading provider of specialized nucleic acid products and services. The $20,000 firm-fixed-price contract is for the provision of custom oligonucleotide and RNA synthesis services to support NIAID's research and public health initiatives. This is a Blanket Purchase Agreement (BPA) call order under...
This is a firm-fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH), to Integrated DNA Technologies, Inc. (IDT) for the supply of twelve (12) antisense oligonucleotides (ASOs) for an in-vivo neurotoxicity study. The contract has a ceiling value of $11,940.00 and a period of performance through March 26, 2026. This purchase order does not have a set-aside designation. IDT is a leading...
This non-competitive contract award from the National Institutes of Health's National Center for Advancing Translational Sciences to Integrated DNA Technologies, Inc. is for $20,026.50 to provide custom synthesis of nine antisense oligonucleotides for a neurotoxicology study. Per the solicitation, IDT will synthesize the oligos using proprietary machines and deliver the highest accuracy in sequence. They will also offer design support and expertise. The period of performance is August 7-21,...